用低抗原含量白喉、破伤风和百日咳疫苗对成人进行加强免疫：接种疫苗5年后的免疫原性。
Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination.
作者信息
McIntyre Peter B, Burgess Margaret A, Egan Annemarie, Schuerman Lode, Hoet Bernard
机构信息
National Centre for Immunisation Research and Surveillance, University of Sydney and The Children's Hospital at Westmead, Australia.
出版信息
Vaccine. 2009 Feb 11;27(7):1062-6. doi: 10.1016/j.vaccine.2008.11.102. Epub 2008 Dec 16.
At 60 months post-vaccination, adults (mean age 45.6 years) randomised to receive combined reduced-antigen-content diphtheria-tetanus and acellular pertussis vaccine (dTpa) versus tetanus-diphtheria (Td)+monovalent acellular pertussis (pa) were seroprotected against diphtheria (> or =0.016IU/mL Vero cell assay) and tetanus (> or =0.1IU/mL ELISA assay) in 94.4% and 96.2%, respectively (dTpa), compared with 93.7% and 90.6% (Td+pa). Anti-FHA, anti-PT and anti-PRN antibodies (> or =5EL.U/mL) were maintained in 100%, 89.5% and 95.0% of dTpa versus 100%, 85.5% and 90.6% of pa vaccine recipients. At 5 years post boosting, antibody levels to diphtheria and tetanus are similar amongst adults receiving a dTpa or dT, and pertussis antibodies remain above pre-booster levels in at least 85%.
在接种疫苗60个月后，随机接受联合低抗原含量白喉-破伤风和无细胞百日咳疫苗（dTpa）的成年人（平均年龄45.6岁）与接受破伤风-白喉（Td）+单价无细胞百日咳疫苗（pa）的成年人相比，分别有94.4%和96.2%的人对白喉（Vero细胞试验≥0.016IU/mL）和破伤风（ELISA试验≥0.1IU/mL）产生了血清保护，而接受Td+pa的比例分别为93.7%和90.6%。dTpa疫苗接种者中100%、89.5%和95.0%的人维持了抗丝状血凝素（FHA）、抗百日咳毒素（PT）和抗百日咳黏附素（PRN）抗体（≥5EL.U/mL），而pa疫苗接种者的相应比例分别为100%、85.5%和90.6%。在加强免疫5年后，接受dTpa或Td的成年人中，对白喉和破伤风的抗体水平相似，并且至少85%的人百日咳抗体仍高于加强免疫前的水平。
Zotero 插件